ABSTRACT
End-stage renal disease (ESRD) carries a significant risk for sudden cardiac arrest (SCA), hospitalization and mortality. We present a case of a vintage hemodialysis patient who had a catastrophic event during his hemodialysis treatment - a sudden cardiac arrest. This case raises several important issues: First, patients with chronic kidney disease (CKD) (and particularly ESRD) are predisposed to an inordinate risk of SCA; second, the factors leading to SCA in CKD are unique; and lastly, it is of paramount importance to have basic life support training, crash carts and defibrillators in dialysis units. It also raises the important discussion regarding the role for automated implantable cardioverter defibrillators and medical therapy for the prevention of SCA in this population.
Subject(s)
Death, Sudden, Cardiac/etiology , Heart Arrest/etiology , Kidney Failure, Chronic/complications , Ventricular Fibrillation/etiology , Aged , Cardiopulmonary Resuscitation , Coronary Angiography , Death, Sudden, Cardiac/prevention & control , Defibrillators, Implantable , Electric Countershock/instrumentation , Electrocardiography , Heart Arrest/diagnosis , Heart Arrest/therapy , Humans , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/therapy , Male , Renal Dialysis , Risk Factors , Treatment Outcome , Ventricular Fibrillation/diagnosis , Ventricular Fibrillation/therapyABSTRACT
BACKGROUND: Hypertension (HTN) is one of the major causes of cardiovascular morbidity and mortality. The objective of the study was to investigate the burden and predictors of HTN in India. METHODS: 6120 subjects participated in the Screening and Early Evaluation of Kidney disease (SEEK), a community-based screening program in 53 camps in 13 representative geographic locations in India. Of these, 5929 had recorded blood pressure (BP) measurements. Potential predictors of HTN were collected using a structured questionnaire for SEEK study. RESULTS: HTN was observed in 43.5% of our cohort. After adjusting for center variation (p < 0.0001), predictors of a higher prevalence of HTN were older age ≥ 40 years (p < 0.0001), BMI of ≥ 23 Kg/M2 (p < 0.0004), larger waist circumference (p < 0.0001), working in sedentary occupation (p < 0.0001), having diabetes mellitus (p < 0.0001), having proteinuria (p < 0.0016), and increased serum creatinine (p < 0.0001). High school/some college education (p = 0.0016), versus less than 9th grade education, was related with lower prevalence of HTN. Of note, proteinuria and CKD were observed in 19% and 23.5% of HTN subjects. About half (54%) of the hypertensive subjects were aware of their hypertension status. CONCLUSIONS: HTN was common in this cohort from India. Older age, BMI ≥ 23 Kg/M2, waist circumference, sedentary occupation, education less, diabetes mellitus, presence of proteinuria, and raised serum creatinine were significant predictors of hypertension. Our data suggest that HTN is a major public health problem in India with low awareness, and requires aggressive community-based screening and education to improve health.
Subject(s)
Cost of Illness , Hypertension, Renal/diagnosis , Hypertension, Renal/mortality , Kidney Diseases/diagnosis , Kidney Diseases/mortality , Mass Screening/statistics & numerical data , Adult , Early Diagnosis , Female , Humans , India/epidemiology , Male , Middle Aged , Prevalence , Prognosis , Risk Assessment , Survival RateABSTRACT
Cryptococcal meningitis is a life-threatening infection commonly seen in patients with advanced HIV infection and solid organ transplant recipients. We report a case of cryptococcal meningitis with immune reconstitution syndrome (IRIS) who presented to us with a headache and complete loss of vision in the left eye. He was managed with antifungals and a short course of steroids, and he regained vision completely. In the hospital, he developed complications including tacrolimus toxicity, fluconazole-induced QT prolongation, and flucytosine-induced thrombocytopenia. Our case demonstrates the importance of a multidisciplinary approach in the management of complex cases like cryptococcal meningitis in solid organ transplant recipients.
Subject(s)
HIV Infections , Immune Reconstitution Inflammatory Syndrome , Meningitis, Cryptococcal , Organ Transplantation , Male , Humans , Meningitis, Cryptococcal/complications , Meningitis, Cryptococcal/drug therapy , HIV Infections/complications , Immune Reconstitution Inflammatory Syndrome/complications , Immune Reconstitution Inflammatory Syndrome/drug therapy , Antifungal Agents/adverse effects , Adrenal Cortex Hormones , Blindness , Organ Transplantation/adverse effectsABSTRACT
Immunoglobulin A nephropathy (IgAN) is the most frequent glomerular disease with rapid development to end stage renal disease, requiring renal replacement therapy. Genome-wide studies suggest geographical variations in genetic susceptibility to IgAN and disease progression. Specific 'candidate genes' were indicated to correlate with different functions that are involved in the pathogenesis of renal conditions. MicroRNAs (miRNAs/miRs) have a major role in mRNA degradation or translation repression, thereby regulating the expression of their target proteins. Previously, a small number of miRNAs were reported to have direct associations with IgAN. In the present study, new miRNAs linked to IgAN were identified in the Indian population. The miRNA was isolated from kidney biopsies of patients with IgAN (n=6) and healthy control tissue from patients with renal cell carcinoma (n=6). The sequencing results indicated that the miRNA percentage acquired from controls and patients with IgAN was 5.61 and 4.35%, respectively. From the results, 10 upregulated and 15 downregulated miRNAs were identified. Of the 25 differentially expressed miRNAs (DEMs), miR-181a-5p, miR-28-3p, let-7g-5p, miR-92a-3p and miR-30c-5p were not reported previously. Furthermore, Kyoto Encyclopedia of Genes and Genomes and Gene Ontology analyses suggested that the target genes of the DEMs were mainly enriched in pathways such as cancer, ErbB signalling, proteoglycans in cancer, Hippo signalling and MAPK pathways. The newly identified miRNAs may impact the behaviour of tissues or IgA deposition by regulating signalling pathways, which forms a basis for future studies aimed at improving the diagnosis and care of patients with IgAN in the Indian community.
ABSTRACT
BACKGROUND: More strokes were observed in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) among patients assigned to darbepoetin alfa. We sought to identify baseline characteristics and postrandomization factors that might explain this association. METHODS AND RESULTS: A multivariate logistic regression model was used to identify baseline predictors of stroke in 4038 patients with diabetes mellitus, chronic kidney disease, and anemia randomized to receive darbepoetin alfa or placebo. To determine whether postrandomization blood pressure, hemoglobin level, platelet count, or treatment dose were responsible for the increased risk related to darbepoetin alfa, we performed a nested case-control analysis (1:10 matching) identifying nonstroke controls with propensity matching. The risk of stroke was doubled with darbepoetin alfa. Overall, 154 patients had a stroke, 101/2012 (5.0%) in the darbepoetin alfa arm and 53/2026 (2.6%) in the placebo arm (hazard ratio 1.9; 95% confidence interval, 1.4-2.7). Independent predictors of stroke included assignment to darbepoetin alfa (odds ratio 2.1; 95% confidence interval, 1.5-2.9), history of stroke (odds ratio 2.0; 95% confidence interval, 1.4-2.9), more proteinuria, and known cardiovascular disease. In patients assigned to darbepoetin alfa, postrandomization systolic and diastolic blood pressure, hemoglobin level, platelet count, and darbepoetin alfa dose did not differ between those with and without stroke. Additional sensitivity analyses using maximal values, latest values, or changes over varying periods of exposure yielded similar results. CONCLUSIONS: The 2-fold increase in stroke with darbepoetin alfa in TREAT could not be attributed to any baseline characteristic or to postrandomization blood pressure, hemoglobin, platelet count, or dose of treatment. These readily identifiable factors could not be used to mitigate the risk of darbepoetin alfa-related stroke. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT00093015.
Subject(s)
Anemia/drug therapy , Anemia/epidemiology , Diabetes Mellitus, Type 2/epidemiology , Erythropoietin/analogs & derivatives , Renal Insufficiency, Chronic/epidemiology , Stroke/epidemiology , Stroke/prevention & control , Aged , Case-Control Studies , Darbepoetin alfa , Erythropoietin/administration & dosage , Female , Follow-Up Studies , Hematinics/administration & dosage , Humans , Incidence , Logistic Models , Male , Middle Aged , Multivariate Analysis , Predictive Value of Tests , Prospective Studies , Risk Factors , Risk Reduction Behavior , Treatment OutcomeABSTRACT
BACKGROUND: Compared to the intravenous route, subcutaneous administration of epoetin requires lower dose and will be an attractive option for cost containment when bundling for dialysis is implemented. Hemoglobin variability defined as fluctuation of hemoglobin over time has not been well studied with respect to the route of administration. METHODS: 157 prevalent-hemodialysis subjects were analyzed from an open-label, randomized study that compared the intravenous to the subcutaneous route of epoetin with identical weight-based dosing algorithm. Hemoglobin variability was defined as the number of weeks hemoglobin is outside the target range of 10-11 g/dl. Sensitivity analysis was performed. RESULTS: 78 subjects in the intravenous and 79 in the subcutaneous group entered the 24-week dose maintenance phase. Baseline covariates were similar in both groups except for the dose of epoetin (lower in subcutaneous) and dialysis vintage (longer in intravenous). Patients on subcutaneous epoetin were outside the target range more weeks (p = 0.04) and had higher standard deviation of hemoglobin (p = 0.01) compared to the intravenous group. CONCLUSIONS: The subcutaneous route of epoetin was associated with modestly higher hemoglobin variability, probably reflecting greater sensitivity of the subcutaneous route and/or identical epoetin-dosing algorithm employed in both the arms. This study could serve as an important guide when bundling for dialysis services is implemented as switching from intravenous to subcutaneous administration is likely to occur.
Subject(s)
Anemia/prevention & control , Erythropoietin/administration & dosage , Hematinics/administration & dosage , Hemoglobins/metabolism , Kidney Failure, Chronic/complications , Aged , Anemia/etiology , Cohort Studies , Epoetin Alfa , Female , Humans , Injections, Intravenous , Injections, Subcutaneous , Kidney Failure, Chronic/therapy , Male , Middle Aged , Randomized Controlled Trials as Topic , Recombinant Proteins , Renal DialysisABSTRACT
Inflammatory cytokines are important predictors of cardiovascular mortality especially in patients with chronic kidney disease. Here we explored the relationship of anemia and epoetin treatment to inflammatory cytokine levels in patients with chronic kidney disease. One hundred non-dialysis patients with chronic kidney disease over 18 years of age were evenly split into anemic and non-anemic cohorts. Of the 50 anemic patients, 23 were receiving erythropoiesis stimulating agents treatments. Levels of tumor necrosis factor (TNF)-alpha were found to be significantly higher and serum albumin was significantly lower with trends towards higher interleukin (IL)-6 and IL-8 in anemic compared to non-anemic patients. Further analysis by multiple logistic regression found that anemic patients treated with erythropoiesis stimulating agents had significantly higher odds for the upper two quartiles for IL-6, IL-8 and TNF-alpha compared to non-anemic patients. Our study found that the anemia of chronic kidney disease was associated with up regulation of TNF-alpha, and possibly IL-6 and IL-8 along with increased levels of these proinflammatory cytokines in patients treated with epoetin.
Subject(s)
Anemia/pathology , Cytokines/analysis , Erythropoietin/pharmacology , Hematinics/pharmacology , Inflammation/diagnosis , Kidney Diseases/pathology , Middle Aged , Aged , Biomarkers/analysis , Case-Control Studies , Chronic Disease , Epoetin Alfa , Erythropoietin/therapeutic use , Female , Hematinics/therapeutic use , Humans , Interleukin-6/analysis , Interleukin-8/analysis , Kidney Diseases/complications , Male , Recombinant Proteins , Tumor Necrosis Factor-alpha/analysis , Up-RegulationABSTRACT
BACKGROUND/AIMS: Anemia in chronic kidney disease is an independent predictor of cardiovascular disease (CVD). We explored the relationship between anemia and markers of inflammation and endothelial activation in non-dialysis chronic kidney disease (ND-CKD) patients to understand this mechanism. METHODS: Cross-sectional analysis was performed on 30 adult ND-CKD patients for markers of inflammation and endothelial activation using a multiplexed immunoassay. Data were analyzed according to the anemic status defined by the modified World Health Organization criteria. RESULTS: Seventeen patients were classified as anemic. Baseline characteristics by anemic status were similar except that anemic patients were older (p = 0.006), had lower estimated glomerular filtration rate (eGFR; p = 0.01) and higher prevalence of CVD (p = 0.02). Compared to non-anemic patients, log-transformed values of fibrinogen (p = 0.012); von Willebrand factor (vWF, p = 0.008), vascular cell adhesion molecule-1 (VCAM-1, p = 0.025) and C-reactive protein (p = 0.043) were elevated in anemic patients. Serum ferritin (p = 0.93) and serum albumin (p = 0.06) were not different. Age and eGFR-adjusted logistic regression analysis showed that anemic patients had increased odds for a composite of higher median values of fibrinogen, vWF and VCAM-1 (p = 0.01, odds ratio 8.1, 95% CI 1.08-111.0). CONCLUSION: We report the association of anemia with elevated markers of endothelial activation in ND-CKD patients. Longitudinal studies are needed to confirm our findings.
Subject(s)
Anemia/blood , Anemia/etiology , Cytokines/blood , Endothelium, Vascular/metabolism , Immunologic Factors/blood , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/complications , Aged , Female , Humans , Male , Middle Aged , Renal DialysisABSTRACT
Anecdotal reports of acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome) with cytomegalovirus (CMV) suggested as the etiological agent have been described in transplant recipients with poor prognosis. We describe a 48-year-old man, a cadaveric renal allograft recipient on cyclosporine, mycophenolate mofetil and prednisolone, who developed febrile illness with unexplained anemia followed by progressive weakness of the upper and lower limbs. He was diagnosed as a case of Guillain-Barré syndrome (GBS). His CMV serology was positive by polymerase chain reaction (PCR). We treated him with both gancyclovir and intravenous immunoglobulins within a week of the onset of GBS and observed rapid recovery. Thus, search for CMV is warranted in transplant patients presenting with GBS, as early initiation of treatment with gancyclovir and immunoglobulins can help expedite recovery.
Subject(s)
Cytomegalovirus Infections/epidemiology , Guillain-Barre Syndrome/epidemiology , Kidney Transplantation , Postoperative Complications/virology , Antiviral Agents/therapeutic use , Cadaver , Comorbidity , Ganciclovir/therapeutic use , Humans , Immunoglobulins, Intravenous/therapeutic use , Kidney Transplantation/adverse effects , Male , Middle Aged , Polycystic Kidney, Autosomal Recessive/surgery , Transplantation, HomologousSubject(s)
Erythropoietin/adverse effects , Kidney Failure, Chronic/complications , Red-Cell Aplasia, Pure/chemically induced , Epoetin Alfa , Humans , Kidney Failure, Chronic/drug therapy , Kidney Failure, Chronic/etiology , Male , Middle Aged , Nephritis, Interstitial/complications , Recombinant Proteins , Renal DialysisSubject(s)
Anemia/blood , Anemia/etiology , Hemoglobins/metabolism , Renal Dialysis/adverse effects , Aged , Anemia/drug therapy , Arteriovenous Shunt, Surgical/adverse effects , Disorders of Excessive Somnolence/etiology , Erythropoietin/administration & dosage , Erythropoietin/adverse effects , Female , Humans , Hypoglycemia/etiology , Iatrogenic Disease , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/etiology , Kidney Failure, Chronic/therapy , Polycythemia/etiology , Recombinant ProteinsABSTRACT
Erythropoietin has transformed the treatment of the anemia of chronic kidney disease (CKD) by preventing the need for blood transfusions and improving the quality of life in all patients, including children. Anemia in children, in the age group 1-19 years, may be defined as hemoglobin (Hgb) levels < 12.1-13.5 g/dl for boys and < 11.4-11.5 g/dl for girls, based on the National Health and Nutrition Examination Survey (NHANES) norms. The prevalence of anemia in children ranges from 31.2% in stage 1 CKD to 93.3% in stages 4 and 5 CKD. The recent publication of trials evaluating the optimal hemoglobin level in adult CKD patients has generated considerable uncertainty about the target Hgb level in children with CKD. It is unclear whether generalizing of results from these trials in adults to children is appropriate. Adequately powered, randomized, controlled studies have not been conducted on children, and none to our knowledge are currently planned. The Food and Drug Administration (FDA) offers scant guidance on the Hgb target level for children, other than implying that it should be no different from that for adults. The purpose of this editorial is to critically scrutinize whether there is a benefit to the normalization of anemia in children with CKD and whether adoption of the results from adult studies is appropriate.